Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection

IF 5 2区 医学 Q2 Medicine Translational Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-03 DOI:10.1016/j.tranon.2024.102238
Wei Zhang , Chao Wu , Hanchen Huang , Paulina Bleu , Wini Zambare , Janet Alvarez , Lily Wang , Philip B. Paty , Paul B. Romesser , J. Joshua Smith , X. Steven Chen
{"title":"Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection","authors":"Wei Zhang ,&nbsp;Chao Wu ,&nbsp;Hanchen Huang ,&nbsp;Paulina Bleu ,&nbsp;Wini Zambare ,&nbsp;Janet Alvarez ,&nbsp;Lily Wang ,&nbsp;Philip B. Paty ,&nbsp;Paul B. Romesser ,&nbsp;J. Joshua Smith ,&nbsp;X. Steven Chen","doi":"10.1016/j.tranon.2024.102238","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC) presents significant challenges in chemotherapy response prediction due to its molecular heterogeneity. Current methods often fail to account for the complexity and variability inherent in individual tumors.</div></div><div><h3>Methods</h3><div>We developed a novel approach using matched CRC tumor and organoid gene expression data. We applied Consensus Weighted Gene Co-expression Network Analysis (WGCNA) across three datasets: CRC tumors, matched organoids, and an independent organoid dataset with IC50 drug response values, to identify key gene modules and hub genes linked to chemotherapy response, particularly 5-fluorouracil (5-FU).</div></div><div><h3>Findings</h3><div>Our integrative analysis identified significant gene modules and hub genes associated with CRC chemotherapy response. The predictive model built from these findings demonstrated superior accuracy over traditional methods when tested on independent datasets. The matched tumor-organoid data approach proved effective in capturing relevant biomarkers, enhancing prediction reliability.</div></div><div><h3>Interpretation</h3><div>This study provides a robust framework for improving CRC chemotherapy response predictions by leveraging matched tumor and organoid gene expression data. Our approach addresses the limitations of previous methods, offering a promising strategy for personalized treatment planning in CRC. Future research should aim to validate these findings and explore the integration of more comprehensive drug response data.</div></div><div><h3>Funding</h3><div>This research was supported by US National Cancer Institute grant R37CA248289, and Sylvester Comprehensive Cancer Center. which receives funding from the National Cancer Institute award P30CA240139. This work was supported by National Institutes of Health (NIH) under the following grants: T32CA009501-31A1 and R37CA248289. This work was also supported by the MSK P30CA008748 grant.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"52 ","pages":"Article 102238"},"PeriodicalIF":5.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11754497/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324003644","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Colorectal cancer (CRC) presents significant challenges in chemotherapy response prediction due to its molecular heterogeneity. Current methods often fail to account for the complexity and variability inherent in individual tumors.

Methods

We developed a novel approach using matched CRC tumor and organoid gene expression data. We applied Consensus Weighted Gene Co-expression Network Analysis (WGCNA) across three datasets: CRC tumors, matched organoids, and an independent organoid dataset with IC50 drug response values, to identify key gene modules and hub genes linked to chemotherapy response, particularly 5-fluorouracil (5-FU).

Findings

Our integrative analysis identified significant gene modules and hub genes associated with CRC chemotherapy response. The predictive model built from these findings demonstrated superior accuracy over traditional methods when tested on independent datasets. The matched tumor-organoid data approach proved effective in capturing relevant biomarkers, enhancing prediction reliability.

Interpretation

This study provides a robust framework for improving CRC chemotherapy response predictions by leveraging matched tumor and organoid gene expression data. Our approach addresses the limitations of previous methods, offering a promising strategy for personalized treatment planning in CRC. Future research should aim to validate these findings and explore the integration of more comprehensive drug response data.

Funding

This research was supported by US National Cancer Institute grant R37CA248289, and Sylvester Comprehensive Cancer Center. which receives funding from the National Cancer Institute award P30CA240139. This work was supported by National Institutes of Health (NIH) under the following grants: T32CA009501-31A1 and R37CA248289. This work was also supported by the MSK P30CA008748 grant.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过匹配结直肠肿瘤-类器官基因表达分析和基于网络的生物标志物选择增强化疗反应预测。
背景:结直肠癌(CRC)由于其分子异质性,在化疗反应预测方面面临重大挑战。目前的方法往往不能解释单个肿瘤固有的复杂性和可变性。方法:我们开发了一种新的方法,使用匹配的CRC肿瘤和类器官基因表达数据。我们将共识加权基因共表达网络分析(WGCNA)应用于三个数据集:CRC肿瘤、匹配的类器官和具有IC50药物反应值的独立类器官数据集,以确定与化疗反应相关的关键基因模块和枢纽基因,特别是5-氟尿嘧啶(5-FU)。研究结果:我们的综合分析确定了与结直肠癌化疗反应相关的重要基因模块和中心基因。根据这些发现建立的预测模型在独立数据集上进行测试时显示出优于传统方法的准确性。匹配肿瘤-类器官数据方法在捕获相关生物标志物方面被证明是有效的,提高了预测的可靠性。解释:这项研究通过利用匹配的肿瘤和类器官基因表达数据,为改善结直肠癌化疗反应预测提供了一个强大的框架。我们的方法解决了以前方法的局限性,为CRC的个性化治疗计划提供了一个有希望的策略。未来的研究应旨在验证这些发现,并探索整合更全面的药物反应数据。本研究由美国国家癌症研究所资助R37CA248289和Sylvester综合癌症中心支持。该项目由国家癌症研究所资助,项目编号为P30CA240139。这项工作得到了美国国立卫生研究院(NIH)的支持,拨款如下:T32CA009501-31A1和R37CA248289。这项工作也得到了MSK P30CA008748基金的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
期刊最新文献
PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients Integrated spatial and single‑cell transcriptomics maps disulfidptosis in renal cell carcinoma and reveals PDLIM1 as a prognostic biomarker and potential therapeutic target STC2-mediated calcium homeostasis dysregulation in the osteosarcoma microenvironment: Insights from single-cell sequencing and machine learning Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1